Insider · CIK 0001857256
Caryn Peterson
Files at GOSS (Gossamer Bio, Inc.). First filing -, latest -.
In brief
Caryn Peterson files SEC Form 4 as officer at GOSS (Gossamer Bio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Caryn Peterson has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 30 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 24, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,800,051 | $0.00 | $0 | 5,800,051 | Aug 26, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -506,250 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -440,000 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -375,000 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -125,000 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -157,500 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -157,500 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -126,667 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,167 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,834 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,784 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,167 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -32,334 | - | - | 0 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +506,250 | - | - | 506,250 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +440,000 | - | - | 440,000 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +375,000 | - | - | 375,000 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | - | - | 125,000 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +157,500 | - | - | 157,500 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +157,500 | - | - | 157,500 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +126,667 | - | - | 126,667 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +21,167 | - | - | 21,167 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +18,834 | - | - | 18,834 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +22,784 | - | - | 22,784 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +9,167 | - | - | 9,167 | Mar 20, 2026 |
| Mar 19, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +32,334 | - | - | 32,334 | Mar 20, 2026 |
| Jan 2, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Common Stock | +84,500 | $0.00 | $0 | 259,333 | Jan 5, 2026 |
| Jan 2, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +506,250 | $0.00 | $0 | 506,250 | Jan 5, 2026 |
| Oct 1, 2025 | GOSS Gossamer Bio, Inc. | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 174,833 | Oct 2, 2025 |
| Mar 4, 2025 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +440,000 | $0.00 | $0 | 440,000 | Mar 6, 2025 |
| Nov 20, 2023 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Nov 22, 2023 |
Questions about Caryn Peterson
Answered from the filings on this page, as of the latest one.
Is Caryn Peterson buying or selling?
Caryn Peterson has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Caryn Peterson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Caryn Peterson has 0.
Where does Caryn Peterson file Form 4?
Caryn Peterson has filed Form 4 at GOSS (Gossamer Bio, Inc.) as EVP, Regulatory Affairs. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.